FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
The Molecular and Clinical Genetics Panel is weighing the Galleri test's clinical evidence today; Medicare coverage could follow FDA approval
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.